AGM Statement

Uniphar

07/05/2026 07:00

RNS Number : 3015D

Uniphar PLC

07 May 2026

 

 

 

AGM Statement

 

 

Dublin, London | Thursday, 07 May 2026

 

Uniphar plc (the "Company" or "Uniphar") is holding its AGM today at 11am BST at the office of William Fry, LLP, 6th Floor, 2 Grand Canal Square, Dublin 2, D02 A342, Ireland.

 

At the AGM, Maurice Pratt, Chairman of Uniphar, will make the following statement:

 

"I am pleased to report that 2025 was another great year for Uniphar, with the business achieving its fastest rate of organic growth since IPO, with ca. 9% organic gross profit growth. This reinforces the success of our strategy in enhancing our ability to scale the company organically. With each of our three divisions delivering a strong performance, the business achieved 21% adjusted EPS growth in 2025, ahead of the Group's expectations. This was driven by a strong trading performance, lower finance costs and accretion from the €35m share buy-back programme completed in the period.

 

The Group continues to maintain a strong liquidity position, with Net Bank Debt/EBITDA of 1.6x at year end. We have now delivered a significant 6-year EPS CAGR of 16%, and we remain confident of reaching our €200m EBITDA target by 2028, with at least 80% of our growth being organic.

 

I am happy to report that 2026 has started well, with performance in the first four months in line with the Board's expectations. Uniphar remains well positioned to deliver organic gross profit growth across each division in line with previous guidance and to deliver on expectations for the full year.

 

M&A continues to play an important role in Uniphar's growth strategy, and the Group maintains a disciplined approach to capital allocation, while managing an active pipeline of acquisition opportunities to further enhance the Group's growth potential.

 

Sustainability remains a key priority for the Group and shapes how the business operates day-to-day. Based on

our recent double materiality assessment, we have a clear focus across the Environment, Social and

Governance themes and continue to make good progress.

 

Finally, as I retire as Chairman this year, I would like to thank our shareholders for their consistent support over the years. I'd also like to express my pride in what the Uniphar team - management, fellow Directors and all our global colleagues - have achieved thus far. I have every confidence that they will continue to grow the business, constantly finding innovative ways to enhance the services we offer to our healthcare clients and their patients."

 

 

 

--- ENDS ---

 

 

Contact details

Uniphar Group
Tel: +353 (0) 1 428 7777
Allan Smylie, Head of Strategy and IR
Davy (Joint Corporate Broker, Nominated Advisor and
Euronext Growth Listing Sponsor)
Tel: +353 (0) 1 679 6363
Daragh O'Reilly
Niall Gilchrist
Ivan Murphy
RBC Capital Markets (Joint Corporate Broker)
Tel: +44 (0) 20 7653 4000
Jamil Miah
Daniel Saveski
Stifel Nicolaus Europe Limited (Joint Corporate Broker)
Tel: +44 (0) 20 7710 7600
Matt Blawat
Ben Maddison
Francis North
Q4 PR
Tel: +353 (0) 1 475 1444
Iarla Mongey, Public Relations Advisor to Uniphar Group


 

 

About Uniphar plc 

Headquartered in Dublin, Ireland, Uniphar is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Uniphar Pharma, Uniphar Medtech and Uniphar Supply Chain & Retail. The Group is active in Europe, North America, APAC and MENA and delivers to 160+ countries.

 

The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth, and profitability.

 

Uniphar Pharma

Uniphar Pharma operates a global business with high value services across the lifecycle of a pharmaceutical product. We enable pharma and biotech companies to bring innovative medicines to global markets and provide healthcare professionals with access to medicines they cannot source through traditional channels. Our strategy is to build a leading platform to provide the specialist support and expertise needed to improve access to these medicines.

 

Uniphar Medtech

Uniphar Medtech is a leading pan-European medical device distributor and solutions partner. The Group's strategy for Uniphar Medtech is to grow our service offering across Europe and expand our addressable market by serving new specialities and new manufacturers.

 

 

Uniphar Supply Chain & Retail

Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in Ireland with a growing symbol group offering of retail pharmacies. The Group's strategy for Uniphar Supply Chain & Retail is to grow our wholesale market share, our symbol group network and our own brand, in-licenced and consumer products portfolio.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
AGMFLFSEERIRIIR